A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Revumenib (Primary) ; Revumenib (Primary) ; Asparaginase; Cytarabine; Cytarabine; Fludarabine; Prednisone; Prednisone; Vincristine
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 Mar 2024 Status changed from active, no longer recruiting to recruiting.
- 15 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2023 Status changed from not yet recruiting to recruiting.